Immunovant (NASDAQ:IMVT) Stock Price Down 6.4% on Disappointing Earnings

Immunovant, Inc. (NASDAQ:IMVT)’s stock price dropped 6.4% on Thursday following a weaker than expected earnings announcement. The stock traded as low as $33.25 and last traded at $33.2950. Approximately 1,378,728 shares traded hands during trading, a decline of 14% from the average daily volume of 1,611,508 shares. The stock had previously closed at $35.56.

The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same quarter in the previous year, the firm earned ($0.64) earnings per share.

Key Stories Impacting Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant released strong Week 16 results from its difficult-to-treat rheumatoid arthritis study, with response rates that investors viewed as clinically meaningful and supportive of the drug’s potential. Article Title
• Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled, creating another near-term catalyst with topline data expected in the second half of 2026. Article Title
• Positive Sentiment: Immunovant also highlighted a cash balance of about $902 million at quarter-end, which should support ongoing development and help fund a potential commercial launch of IMVT-1402 in Graves’ disease. Article Title

Analyst Ratings Changes

IMVT has been the topic of several recent analyst reports. HC Wainwright increased their target price on Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Guggenheim raised their price objective on Immunovant from $41.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, February 9th. The Goldman Sachs Group raised their price objective on Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a report on Wednesday, April 8th. Finally, Citigroup reaffirmed a “buy” rating on shares of Immunovant in a report on Thursday. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $34.44.

Insider Transactions at Immunovant

In other Immunovant news, CFO Tiago Girao sold 25,760 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total value of $763,011.20. Following the completion of the transaction, the chief financial officer owned 247,596 shares in the company, valued at approximately $7,333,793.52. This represents a 9.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric Venker sold 14,229 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $24.10, for a total transaction of $342,918.90. Following the completion of the transaction, the chief executive officer owned 19,561 shares of the company’s stock, valued at approximately $471,420.10. This trade represents a 42.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 78,141 shares of company stock worth $2,115,713 in the last quarter. 1.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Granahan Investment Management LLC increased its stake in shares of Immunovant by 24.9% during the third quarter. Granahan Investment Management LLC now owns 266,221 shares of the company’s stock valued at $4,291,000 after acquiring an additional 53,133 shares during the period. Aberdeen Group plc increased its stake in shares of Immunovant by 16.2% during the third quarter. Aberdeen Group plc now owns 981,804 shares of the company’s stock valued at $15,827,000 after acquiring an additional 137,099 shares during the period. Alpine Global Management LLC increased its stake in shares of Immunovant by 4.9% during the third quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company’s stock valued at $44,406,000 after acquiring an additional 128,039 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Immunovant during the fourth quarter valued at approximately $1,823,000. Finally, HighVista Strategies LLC increased its stake in shares of Immunovant by 38.5% during the third quarter. HighVista Strategies LLC now owns 253,127 shares of the company’s stock valued at $4,080,000 after acquiring an additional 70,319 shares during the period. Institutional investors and hedge funds own 47.08% of the company’s stock.

Immunovant Stock Down 5.5%

The firm has a market cap of $6.84 billion, a price-to-earnings ratio of -12.45 and a beta of 0.70. The stock’s 50 day moving average is $26.48 and its 200 day moving average is $25.78.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.